Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.34 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 2/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | KRAS | P01116 | 1/20 | 0.31 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6508509 | 0.94 | PTGDR2 (0.35) | FGFR1DDR2PTGDR2MAP3K8KRAS | |
| SCHEMBL6507148 | 0.93 | MAP3K8 (0.40) | MAP3K8ATRKRAS | |
| SCHEMBL6503910 | 0.89 | MAP3K8 (0.33) | FGFR1DDR2PTGDR2MAP3K8KRAS | |
| SCHEMBL6506250 | 0.89 | KRAS (0.34) | PTGDR2MAP3K8KRAS | |
| SCHEMBL6502580 | 0.89 | KRAS (0.33) | MAP3K8ATRKRAS | |
| SCHEMBL6504036 | 0.88 | MAP3K8 (0.33) | MAP3K8ATRKRAS | |
| SCHEMBL6500744 | 0.87 | MAP3K8 (0.34) | MAP3K8KRAS | |
| SCHEMBL6502627 | 0.86 | MAP3K8 (0.35) | MAP3K8KRAS | |
| SCHEMBL6504135 | 0.86 | MAP3K8 (0.33) | MAP3K8 | |
| SCHEMBL6510542 | 0.86 | MAP3K8 (0.36) | MAP3K8ATRKRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090529-A1 | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | PFIZER INC | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090529-A1 | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, CDK4, CDK9 | FGFR1 225/4885DDR2 2394/4885PTGDR2 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.